Udg Healthcare PLC (LON:UDG)‘s stock had its “buy” rating restated by research analysts at N+1 Singer in a research report issued to clients and investors on Thursday. They presently have a GBX 746 ($9.32) target price on the stock. N+1 Singer’s price target would indicate a potential upside of 13.29% from the stock’s current price.

Other research analysts have also issued reports about the company. Goodbody reissued a “buy” rating on shares of Udg Healthcare PLC in a research report on Thursday. Berenberg Bank boosted their price target on Udg Healthcare PLC from GBX 700 ($8.75) to GBX 720 ($9.00) and gave the stock a “buy” rating in a research report on Friday, November 18th. Liberum Capital initiated coverage on Udg Healthcare PLC in a research report on Thursday, October 27th. They issued a “buy” rating and a GBX 750 ($9.37) price target for the company. Numis Securities Ltd reissued an “add” rating and issued a GBX 730 ($9.12) price target on shares of Udg Healthcare PLC in a research report on Monday, October 24th. Finally, Davy Research reissued an “outperform” rating on shares of Udg Healthcare PLC in a research report on Monday, October 24th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Udg Healthcare PLC presently has an average rating of “Buy” and an average target price of GBX 714.33 ($8.92).

Analyst Recommendations for Udg Healthcare PLC (LON:UDG)

Shares of Udg Healthcare PLC (LON:UDG) opened at 625.50 on Thursday. The stock’s market capitalization is GBX 1.54 billion. The company’s 50 day moving average price is GBX 653.93 and its 200 day moving average price is GBX 615.09. Udg Healthcare PLC has a 52-week low of GBX 491.30 and a 52-week high of GBX 692.50.

In related news, insider Chris Corbin sold 90,849 shares of the company’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of GBX 634 ($7.92), for a total transaction of £575,982.66 ($719,618.52).

TRADEMARK VIOLATION WARNING: “N+1 Singer Reaffirms “Buy” Rating for Udg Healthcare PLC (UDG)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2016/11/24/n1-singer-reaffirms-buy-rating-for-udg-healthcare-plc-udg.html.

Udg Healthcare PLC Company Profile

UDG Healthcare plc, formerly United Drug plc, is a healthcare services provider in the Republic of Ireland, the United Kingdom, North America and Continental Europe. The Company operates in three segments. The Ashfield Commercial & Medical Services segment is engaged in the provision of sales, marketing and healthcare communications services to pharmaceutical companies, and it also provides sales teams, healthcare communications, telesales, nurse educators, medical information, pharmacovigilance, regulatory and event management services to over 300 healthcare companies in approximately 20 countries.

Receive News & Stock Ratings for Udg Healthcare PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare PLC and related stocks with our FREE daily email newsletter.